Patient Immunotherapy Summit: Breast Cancer Brief

While one in eight women in the U.S. will develop breast cancer in their lifetime, the good news is that the cancer has an 89% five-year survival outlook. CRI is proud to have Sarah Sammons, MD, the Associate Director of the Metastatic Breast Cancer Program at the Dana-Farber Cancer Institute, further discuss this important type of cancer. Dr. Sammons seeks to improve outcomes for breast cancer patients, particularly for those experiencing the complications of breast cancer metastasis.